NCT02965378 2021-05-27Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerSWOG Cancer Research NetworkPhase 2/3 Completed43 enrolled 15 charts